Shattuck Labs Q3 net loss more than doubles to $25.2 million
Bitget2026/11/05 13:09- Shattuck Labs’ third-quarter 2026 net loss more than doubled year over year to $25.2 million.
- Research and development expenses more than doubled year over year to $21.6 million.
- Cash, cash equivalents and short-term investments totaled $196.3 million at September 30, 2026, with operations expected to be funded into 2029.
- The Phase 2b SL-325 Crohn’s disease trial began, with 12-week induction data expected in the first half of 2028.
- The SL-325 hidradenitis suppurativa Phase 2 trial is expected to begin in fourth-quarter 2026, with data anticipated in first-half 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Saudi Arabia's oil production in October surged by 26%, reaching the highest level since the onset of the conflict, while Brent crude has dropped over 20% this month
OPEC's monthly report shows that Saudi Arabia's average daily crude oil production in October rose to 10.56 million barrels, just several hundred thousand barrels lower than the pre-war level in February and slightly above its quoted limit under the OPEC framework. Iraq's daily output in October also reached approximately 4.9 million barrels, a new high since the outbreak of war. Meanwhile, after the UAE exited OPEC and began competing in the market independently, both the UAE and Saudi Arabia recently slashed their official December cargo prices for Asian buyers, intensifying the competitive landscape.
Scorpio hits gold beyond Nevada resource
Capri Holdings appoints Estée Lauder senior executive Justin Boxford as CEO
Total trading volume reaches $200 millions, @enter_elysium to launch on Monday
Crypto prices
More
